| Autor: |
Bastien L; Departments of Urology and Oncology, INSERM U955Eq07, CHU Mondor Assistance Publique des Hopitaux de Paris, Créteil, France., Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A |
| Jazyk: |
angličtina |
| Zdroj: |
BJU international [BJU Int] 2009 May; Vol. 103 (10), pp. 1334-42. Date of Electronic Publication: 2009 Mar 11. |
| DOI: |
10.1111/j.1464-410X.2009.08454.x |
| Abstrakt: |
The development of targeted molecules in renal carcinogenesis changed the therapeutic approaches of treatment for metastatic clear cell renal cell carcinoma. Four available drugs are currently available, i.e. bevacizumab, sunitinib, sorafenib and temsirolimus, but other molecules and combined therapy are under investigation. In this review we assess published reports of these targeted therapies and discuss the novel promising molecules targeting vascular endothelial growth factor and its receptors, the mammalian target of rapamycin and epithelial growth factor cascade. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
